ARTICLE | Clinical News
Atrix begins four-month Leuprogel trial
January 29, 2001 8:00 AM UTC
ATRX began a Phase III trial of its Leuprogel four-month, 30 mg leuprolide acetate subcutaneous depot injection to treat advanced prostate cancer. Leuprogel is also in Phase III testing as a monthly i...